Headline USA Politics

Pfizer May Have Its Coronavirus Vaccine Ready In November, But It Will Not Arrive Before Elections | The NY Journal

On several occasions, President Donald Trump has said that a vaccine to curb COVID-19 would be approved for use before November 3.

Pfizer Pharmaceutical hopes to apply in November for emergency authorization for the vaccine it is developing against the coronavirus, but It will not be before the presidential elections on November 3, as promised Donald trump.

As reported this Friday by the executive director of the company, Albert Bourla, Pfizer just in the third week of November will apply to obtain emergency authorization from the Food and Drug Administration (FDA).

Bourla said in a statement that although the pharmaceutical company will know by the end of October if the vaccine works, they will need additional time to collect safety and manufacturing data, which will extend the schedule at least until the last weeks of November.

[La falta de pruebas pone en duda el uso de la vacuna del coronavirus en niños durante los primeros meses]

The announcement marks a departure from previous statements provided by Pfizer, which emphasized that the vaccine could be ready in October, before the election.

That fulfilled the wish of Trump, who repeatedly claimed that a vaccine to curb COVID-19 would be approved for use by November 3.

[Fact check: Trump dice que la vacuna del COVID-19 estará lista en octubre. Pero esto es improbable]

Emergency authorization is a power that the FDA has to approve the use of a drug in a more agile and rapid resolution process, avoiding weeks or months of analysis of the studies presented by a pharmaceutical company.

The FDA will tighten the requirements to approve an emergency vaccine against COVID-19, in an attempt to show transparency and build trust in the public, according to The Washington Post.

To get to request that authorization, Pfizer still has to wait for the results of its vaccine to be positive.

Other pharmaceutical companies seeking the coronavirus vaccine have faced difficulties.

At the beginning of September, the AstraZeneca laboratory suspended its tests in volunteers of the vaccine that it develops together with the University of Oxford in the United Kingdom, after the appearance of “a potentially unexplained disease” in one of the volunteers.

[El mundo ha gastado 21,000 millones de dólares en el desarrollo de la vacuna]

And this week, Johnson & Johnson announced that it will suspend clinical trials of its vaccine due to adverse reactions in volunteers who received the doses. The pharmacy did not say what the disease affects them.

Infectious disease expert Anthony Fauci said that the interruption of the trials is an “unfortunate” fact, although he clarified that it is something that can happen frequently in view of the precautions for the safety of the patients.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *